Breast cancer
Stories
-
FDA approves tucatinib with trastuzumab and pertuzumab for HER2-positive breast cancer
On October 7, 2026, the FDA approved Tukysa with trastuzumab and pertuzumab as maintenance treatment for HER2-positive breast cancer. The FDA said median progression-free survival was 24.9 months with tucatinib and 16.3 months with placebo.